Chromogranin A : as a tumor marker for neuroendocrine tumors diagnosis, follow-up and its correlation with response to somatosttin analogues
Author
al-Naqqash, Minwar A. Muhammad
Source
Journal of the Faculty of Medicine Baghdad
Issue
Vol. 58, Issue 4 (31 Dec. 2016), pp.307-311, 5 p.
Publisher
University of Baghdad Faculty of Medicine
Publication Date
2016-12-31
Country of Publication
Iraq
No. of Pages
5
Main Subjects
Abstract EN
Background: Chromogranin A is a useful tumor marker for neuroendocrine tumors (NETs) diagnosis & follow-up, Octreotide (somatostatin-long acting repeatable (SAS-LAR)) is an established treatment for NETs.
Studies regarding the relation between response to SAS-LAR & the change in Chromogranin A (CgA) plasma level are still lacking.
Objectives: To determine the association between the using of Octreotide (SAS-LAR) and CgA level on time sequence & clinical status.
Patients & methods: a prospective observational study included 38 neuroendocrine patients in The Oncology Teaching Hospital/medical city complex/Baghdad, started at September 2013 till May 2016; assessing their circulating chromogranin A (CgA) plasma levels on multiple occasions(0,2 and 4 months) by ELISA technique and its correlation with response to somatostatin analogues (SAS-LAR) in those patients.
Results: the study recruited 38 neuroendocrine patients.
21 (55%) of them were males, 23 (60%) patients were older than 50 years old & 17 (44%) had metastasis to different sites.
Somatostatin analogues (octreotide 30mg) was administered to 20 out of 38 (52.6%) studied patients.
Serial CgA tests were performed in (17 out of 20) patients used SAS-LAR, with a change in mean value from (225.3 U/L) pre-using the agent to (17.5 U/L) two months after its use & to (8.7 U/L) four months after its use (p=0.009, p=0.002 respectively) while the change in mean of CgA level was from (205.9 U/L) to (200.9 U/L) in 10 patients who did not use Octreotide (p=0.2).Also results showed that no statistically significant difference in mean value of CgA pre & two months after using Octreotide with regard to grade of the tumor.
Conclusions: Plasma CgA is a reliable marker for NETs (regarding diagnosis, prognosis and response to treatment including somatostatin analogues).All patients with NETs should undergo a baseline plasma CgA level at diagnosis.
Serial assessment of circulating CgA could be done for NET patients when there is baseline elevation of CgA level in circulation.
American Psychological Association (APA)
al-Naqqash, Minwar A. Muhammad. 2016. Chromogranin A : as a tumor marker for neuroendocrine tumors diagnosis, follow-up and its correlation with response to somatosttin analogues. Journal of the Faculty of Medicine Baghdad،Vol. 58, no. 4, pp.307-311.
https://search.emarefa.net/detail/BIM-761041
Modern Language Association (MLA)
al-Naqqash, Minwar A. Muhammad. Chromogranin A : as a tumor marker for neuroendocrine tumors diagnosis, follow-up and its correlation with response to somatosttin analogues. Journal of the Faculty of Medicine Baghdad Vol. 58, no. 4 (2016), pp.307-311.
https://search.emarefa.net/detail/BIM-761041
American Medical Association (AMA)
al-Naqqash, Minwar A. Muhammad. Chromogranin A : as a tumor marker for neuroendocrine tumors diagnosis, follow-up and its correlation with response to somatosttin analogues. Journal of the Faculty of Medicine Baghdad. 2016. Vol. 58, no. 4, pp.307-311.
https://search.emarefa.net/detail/BIM-761041
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 310-311
Record ID
BIM-761041